Withdrawn study sought to peer inside the MS brain

This study aimed to understand how the drug alemtuzumab affects brain inflammation in people with relapsing-remitting multiple sclerosis (MS). Researchers planned to use a special type of brain scan (PET) to measure inflammation before and after treatment. The goal was to learn if reducing this inflammation is how the drug helps slow disease progression and improve symptoms like fatigue. The study was withdrawn before any participants were enrolled.